UY30758A1 - Formas cristalinas del acido (3s)-3-[n-(n'-(-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico, composiciones farmacéuticas conteniéndolas y aplicaciones. - Google Patents

Formas cristalinas del acido (3s)-3-[n-(n'-(-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico, composiciones farmacéuticas conteniéndolas y aplicaciones.

Info

Publication number
UY30758A1
UY30758A1 UY30758A UY30758A UY30758A1 UY 30758 A1 UY30758 A1 UY 30758A1 UY 30758 A UY30758 A UY 30758A UY 30758 A UY30758 A UY 30758A UY 30758 A1 UY30758 A1 UY 30758A1
Authority
UY
Uruguay
Prior art keywords
crystalline forms
pharmaceutical compositions
amino
tetrafluorofenoxi
oxopentanoico
Prior art date
Application number
UY30758A
Other languages
English (en)
Inventor
Jason Hanko
Stuart Dimmock
Eric J Hagen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY30758A1 publication Critical patent/UY30758A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invencion se refiere a formas cristalinas del acido ( 3S)-3[N-(N?? -(2-tercbutifenil)oxamil)alaninil]amino-5-(-2`,3??,5??,6??-tetrafluorofenoxil)-4-oxopentanoico (vease la formula I ). La invencion se refiere además a composiciones farmacéuticas que comprenden dichas formas cristalinas y a la utilizacion de dichas composiciones farmacéuticas y dichas formas cristalinas en el tratamiento de varias afecciones particularmente en el tratamiento de la fibrosis hepática.
UY30758A 2006-12-06 2007-12-04 Formas cristalinas del acido (3s)-3-[n-(n'-(-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico, composiciones farmacéuticas conteniéndolas y aplicaciones. UY30758A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86874806P 2006-12-06 2006-12-06

Publications (1)

Publication Number Publication Date
UY30758A1 true UY30758A1 (es) 2008-07-31

Family

ID=39205161

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30758A UY30758A1 (es) 2006-12-06 2007-12-04 Formas cristalinas del acido (3s)-3-[n-(n'-(-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico, composiciones farmacéuticas conteniéndolas y aplicaciones.

Country Status (23)

Country Link
US (1) US7692038B2 (es)
EP (1) EP2091910B1 (es)
JP (1) JP5495787B2 (es)
KR (1) KR101125932B1 (es)
CN (3) CN103951583B (es)
AR (1) AR064809A1 (es)
AU (1) AU2007330478B2 (es)
CA (1) CA2669849C (es)
CL (1) CL2007003491A1 (es)
DK (1) DK2091910T3 (es)
ES (1) ES2524021T3 (es)
HK (3) HK1138567A1 (es)
HN (1) HN2007000536A (es)
IL (1) IL198732A (es)
MX (1) MX2009006055A (es)
NO (1) NO338908B1 (es)
PA (1) PA8759501A1 (es)
PE (1) PE20081251A1 (es)
PL (1) PL2091910T3 (es)
PT (1) PT2091910E (es)
TW (1) TWI345466B (es)
UY (1) UY30758A1 (es)
WO (1) WO2008068615A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104876937B (zh) * 2010-02-12 2017-07-28 辉瑞公司 8‑氟‑2‑{4‑[(甲氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂*并[5,4,3‑cd]吲哚‑6‑酮的马来酸盐、其药物组合物及其用途
CN103113405B (zh) * 2012-10-17 2016-03-02 上海日馨生物科技有限公司 苯磷硫胺多晶型体、制备方法及其应用
KR20240010105A (ko) * 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
SG11201700958YA (en) * 2014-09-08 2017-03-30 Pfizer Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
NZ734041A (en) 2015-01-30 2022-02-25 Vertex Pharma Crystalline forms of c21h22cl2n4o2
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
CN105017061B (zh) * 2015-07-07 2017-03-29 苏州富士莱医药股份有限公司 一种恩利卡生的合成方法
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US20190022043A1 (en) 2015-12-31 2019-01-24 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
JP2019530696A (ja) 2016-10-05 2019-10-24 ノバルティス アーゲー 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物
TWI764977B (zh) * 2017-01-23 2022-05-21 大陸商正大天晴藥業集團股份有限公司 作爲ｃａｓｐａｓｅ抑制劑的聯環化合物、含有其的藥物組合物及其應用
WO2018172950A1 (en) * 2017-03-23 2018-09-27 Novartis Ag Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate
CA3058280C (en) * 2017-03-30 2023-11-28 Merck Patent Gmbh Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
AR114251A1 (es) * 2018-02-13 2020-08-12 Syngenta Participations Ag Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida
WO2020006341A1 (en) 2018-06-29 2020-01-02 Conatus Pharmaceuticals, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
AU2020231396A1 (en) 2019-03-07 2021-10-21 Nobo Medicine Inc. Caspase inhibitors and methods of use thereof
CN111351780A (zh) * 2019-12-29 2020-06-30 中船重工（邯郸）派瑞特种气体有限公司 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
KR102670554B1 (ko) 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149483T1 (de) * 1991-07-30 1997-03-15 Ajinomoto Kk Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
DK0625504T3 (da) * 1993-05-12 1997-12-08 Heumann Pharma Gmbh & Co Stabil og krystallinsk form af Bezafibrat
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en) * 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US7053056B2 (en) * 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
GB9923933D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Lab Novel pharmaceutical
ES2302857T3 (es) * 2001-12-11 2008-08-01 Kyorin Pharmaceutical Co., Ltd. Cristales estables de derivado del acido fenilpropionico sustituido y procedimiento para su produccion.
RU2008101383A (ru) * 2005-07-11 2009-07-20 Пфайзер Лимитед (GB) НОВАЯ КОМБИНАЦИЯ АНТИMAdCAM-АНТИТЕЛА И ПРОТИВОФИБРОЗНОГО ИНГИБИТОРА КАСПАЗЫ ДЛЯ ЛЕЧЕНИЯ ФИБРОЗА ПЕЧЕНИ

Also Published As

Publication number Publication date
CL2007003491A1 (es) 2008-06-20
CN103951583B (zh) 2016-01-06
NO20091892L (no) 2009-06-17
IL198732A (en) 2014-02-27
AR064809A1 (es) 2009-04-29
WO2008068615A8 (en) 2009-05-28
CN103923169B (zh) 2017-05-24
CN101573328B (zh) 2014-04-02
CN101573328A (zh) 2009-11-04
EP2091910B1 (en) 2014-08-20
CN103951583A (zh) 2014-07-30
TWI345466B (en) 2011-07-21
US7692038B2 (en) 2010-04-06
EP2091910A1 (en) 2009-08-26
AU2007330478A1 (en) 2008-06-12
KR20090080113A (ko) 2009-07-23
CA2669849C (en) 2012-01-31
AU2007330478B2 (en) 2011-09-08
PT2091910E (pt) 2014-11-18
DK2091910T3 (en) 2014-12-01
TW200833319A (en) 2008-08-16
CN103923169A (zh) 2014-07-16
HK1200440A1 (zh) 2015-08-07
HK1199885A1 (en) 2015-07-24
HK1138567A1 (en) 2010-08-27
HN2007000536A (es) 2011-01-17
CA2669849A1 (en) 2008-06-12
PL2091910T3 (pl) 2015-02-27
JP5495787B2 (ja) 2014-05-21
NO338908B1 (no) 2016-10-31
PE20081251A1 (es) 2008-09-17
JP2010511689A (ja) 2010-04-15
WO2008068615A1 (en) 2008-06-12
MX2009006055A (es) 2009-06-16
IL198732A0 (en) 2010-02-17
KR101125932B1 (ko) 2012-03-22
ES2524021T3 (es) 2014-12-03
US20080249031A1 (en) 2008-10-09
PA8759501A1 (es) 2009-04-23

Similar Documents

Publication Publication Date Title
UY30758A1 (es) Formas cristalinas del acido (3s)-3-[n-(n'-(-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico, composiciones farmacéuticas conteniéndolas y aplicaciones.
RS52306B (en) CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE CO-CRYSTALS
TW200716568A (en) 1H-quinazoline-2,4-diones
NI200600240A (es) FORMA CRISTALINA Delta-d CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN, Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
PA8629201A1 (es) Polimorfo cristalino de acetato de bazedoxifeno
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
BRPI0518301A2 (pt) inseticidas
BR0311693A (pt) Sal de formato de o-desmetil-venlafaxina
BRPI0913457A2 (pt) "composto, composição farmacêutica, e, uso do composto"
MY153763A (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
BRPI0408347A (pt) derivados de pirimidina
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
ATE540041T1 (de) Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
CR8529A (es) Nueva forma cristalina v de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contiene
GT200900064A (es) Metodos y composiciones para mejorar el estado sanitario de plantas
NO20090175L (no) Stabile laquinimod sammensetninger
TW200642700A (en) Chemically defined stabiliser
CR8615A (es) Polimorfo cristalino de un acetato de bazedoxifeno
DE602008000754D1 (de) Tropanverbindungen
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
BRPI0620229A8 (pt) formulação
TW200738627A (en) Trialkylsilyl-indoles
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
DK1583756T3 (da) Thiophencarboxamider som inhibitorer af enzymet IKK-2

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20191011